I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard
{"title":"Ensifentrine降低COPD患者的医疗资源利用率:Ensifentrine的3期临床试验Enhance-2的结果,Ensifentrine是一种双重PDE3/4抑制剂","authors":"I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard","doi":"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":205419,"journal":{"name":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","volume":"51 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor\",\"authors\":\"I. Barjaktarevic, T. Rheault, T. Bengtsson, K. Rickard\",\"doi\":\"10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":205419,\"journal\":{\"name\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"volume\":\"51 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"B22. NEW TREATMENTS AND NOVEL TARGETS FOR COPD AND ALPHA-1","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a2839","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ensifentrine Reduced Healthcare Resource Utilization in Subjects With COPD: Results From Enhance-2, a Phase 3 Trial of Ensifentrine, a Dual PDE3/4 Inhibitor